IL206880A - An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody - Google Patents

An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody

Info

Publication number
IL206880A
IL206880A IL206880A IL20688010A IL206880A IL 206880 A IL206880 A IL 206880A IL 206880 A IL206880 A IL 206880A IL 20688010 A IL20688010 A IL 20688010A IL 206880 A IL206880 A IL 206880A
Authority
IL
Israel
Prior art keywords
antibody
cadherin
binds
medicament
protein
Prior art date
Application number
IL206880A
Other languages
English (en)
Hebrew (he)
Other versions
IL206880A0 (en
Original Assignee
Adheron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adheron Therapeutics Inc filed Critical Adheron Therapeutics Inc
Publication of IL206880A0 publication Critical patent/IL206880A0/en
Publication of IL206880A publication Critical patent/IL206880A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL206880A 2008-01-11 2010-07-08 An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody IL206880A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1073408P 2008-01-11 2008-01-11
PCT/US2009/000162 WO2009089062A2 (en) 2008-01-11 2009-01-09 Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders

Publications (2)

Publication Number Publication Date
IL206880A0 IL206880A0 (en) 2010-12-30
IL206880A true IL206880A (en) 2014-12-31

Family

ID=40602259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL206880A IL206880A (en) 2008-01-11 2010-07-08 An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody

Country Status (15)

Country Link
US (4) US8591888B2 (https=)
EP (2) EP3181588A1 (https=)
JP (1) JP5511684B2 (https=)
CN (1) CN101952316B (https=)
AU (1) AU2009204467B2 (https=)
BR (1) BRPI0906492A2 (https=)
CA (1) CA2711394A1 (https=)
DK (1) DK2242769T3 (https=)
ES (1) ES2611102T3 (https=)
HU (1) HUE031207T2 (https=)
IL (1) IL206880A (https=)
MX (1) MX2010007551A (https=)
PL (1) PL2242769T3 (https=)
SI (1) SI2242769T1 (https=)
WO (1) WO2009089062A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711394A1 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
KR20190000385A (ko) * 2010-05-04 2019-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
RS57215B1 (sr) * 2010-07-15 2018-07-31 Adheron Therapeutics Inc Humanizovana antitela koja ciljaju ec1 domen kadherina-11 i kompozicije i postupci koji su u vezi sa njima
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR20130142025A (ko) * 2012-06-18 2013-12-27 한국생명공학연구원 카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
WO2016196146A1 (en) * 2015-05-29 2016-12-08 Children's Hospital Medical Center Cdh26 based therapeutic agents and their use
KR101654526B1 (ko) * 2015-10-19 2016-09-06 한국생명공학연구원 카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
WO2017123401A1 (en) 2016-01-13 2017-07-20 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323A (en) * 1851-08-26 colne
US215482A (en) * 1879-05-20 Improvement in spring be d-bottoms
US110755A (en) * 1871-01-03 Improvement in spike-machines
US229811A (en) * 1880-07-13 dtjnlop
US253200A (en) * 1882-02-07 Timothy guilford
US229199A (en) * 1880-06-22 Wood-working machine
US248219A (en) * 1881-10-11 Panorama-toy
US248220A (en) * 1881-10-11 Machine for graining and dicing leather
US96746A (en) * 1869-11-09 Improvement in mechanical movements
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US5859136A (en) * 1997-11-03 1999-01-12 E. I. Du Pont De Nemours And Company Coating composition containing an amine functional dispersed polymer and an isocyanate curing agent
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
EP1075494A2 (en) * 1998-05-05 2001-02-14 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
DK1207905T3 (da) 1999-09-03 2011-01-03 Brigham & Womens Hospital Fremgangsmåder og sammensætninger til behandling af inflammatorisk sygdom under anvendelse af cadherin-II modulerende midler
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US6952969B2 (en) * 2003-09-30 2005-10-11 The Aerospace Corporation Ceramic ball bearing fracture test method
WO2006089397A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
CA2711394A1 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
EP2245067A2 (en) 2008-02-11 2010-11-03 Novartis AG Methods of using cadherin 11 (cdh11) antagonists
AU2010242338B2 (en) * 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
RS57215B1 (sr) 2010-07-15 2018-07-31 Adheron Therapeutics Inc Humanizovana antitela koja ciljaju ec1 domen kadherina-11 i kompozicije i postupci koji su u vezi sa njima

Also Published As

Publication number Publication date
SI2242769T1 (sl) 2017-02-28
US20110045003A1 (en) 2011-02-24
DK2242769T3 (en) 2017-02-06
US20110008323A1 (en) 2011-01-13
US20090253200A1 (en) 2009-10-08
EP2242769B1 (en) 2016-11-02
WO2009089062A8 (en) 2010-09-02
CA2711394A1 (en) 2009-07-16
CN101952316A (zh) 2011-01-19
JP5511684B2 (ja) 2014-06-04
MX2010007551A (es) 2010-11-30
ES2611102T3 (es) 2017-05-04
PL2242769T3 (pl) 2017-06-30
JP2011509094A (ja) 2011-03-24
IL206880A0 (en) 2010-12-30
US9315568B2 (en) 2016-04-19
AU2009204467A1 (en) 2009-07-16
EP2242769A2 (en) 2010-10-27
AU2009204467B2 (en) 2012-09-06
US20140120104A1 (en) 2014-05-01
EP3181588A1 (en) 2017-06-21
US8591888B2 (en) 2013-11-26
CN101952316B (zh) 2015-04-01
WO2009089062A2 (en) 2009-07-16
US7972846B2 (en) 2011-07-05
WO2009089062A3 (en) 2009-09-24
BRPI0906492A2 (pt) 2015-12-01
HUE031207T2 (hu) 2017-07-28

Similar Documents

Publication Publication Date Title
IL206880A (en) An antibody that binds to Cadhrin-11 protein, its use for the preparation of a drug and an isolated nucleic acid encoded for antibody
US9085637B2 (en) Selective PYY compounds and uses thereof
CN110023329B (zh) 作为肽类三重glp1/胰高血糖素/gip受体激动剂的新化合物
KR102476550B1 (ko) 선택적인 pyy 화합물 및 그것의 사용
CN108026153B (zh) 作为选择性肽双重glp-1/胰高血糖素受体激动剂的新毒蜥外泌肽-4衍生物
US8841249B2 (en) Growth hormones with prolonged in-vivo efficacy
US10583172B2 (en) HPYY(1-36) having a beta-homoarginine substitution at position 35
CN109996557A (zh) 作为肽类glp1/胰高血糖素/gip受体激动剂的新化合物
JP2016535087A (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
CZ20023496A3 (cs) Modulátory receptorů pro hormon příštítných tělísek a protein příbuzný s hormonem příštítných tělísek
JP2008530245A5 (https=)
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
CN105727261A (zh) 包含弹性蛋白样肽的治疗剂
JP2014502252A (ja) 作用持続時間が増した改変ポリペプチド
EA200702093A1 (ru) Антитела-миметики glp-1 человека, композиции, способы и их применение
CN103957926A (zh) 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
RU2012123642A (ru) Аналоги инсулина, содержащие хлорированные аминокислоты
NZ735684A (en) Materials and methods for respiratory disease control in canines
CN102652831A (zh) 生物膜的免疫治疗
EP2174951A3 (en) Mutant of granulocyte-colony stimulating factor (G-CSF) and chemically conjugated polypeptide thereof
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
NZ593200A (en) Peptide adjuvants
DE60135650D1 (de) Amidotransferase und dessen expressionsprodukt
US20130225479A1 (en) Methods and Compositions for Treating Inflammation
KR20010024805A (ko) 베타-리포트로핀 및 그의 용도

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees